NO20072461L - Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme - Google Patents

Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme

Info

Publication number
NO20072461L
NO20072461L NO20072461A NO20072461A NO20072461L NO 20072461 L NO20072461 L NO 20072461L NO 20072461 A NO20072461 A NO 20072461A NO 20072461 A NO20072461 A NO 20072461A NO 20072461 L NO20072461 L NO 20072461L
Authority
NO
Norway
Prior art keywords
biphenyl
obesity
preparation
treatment
acid derivatives
Prior art date
Application number
NO20072461A
Other languages
English (en)
Norwegian (no)
Inventor
Roger A Smith
Derek B Lowe
Stephen J O'connor
Tatiana E Shelekhin
Philip Coish
Roger B Clark
Jeffrey Stebbins
Ann-Marie Cambell
Christiana Akuche
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20072461L publication Critical patent/NO20072461L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20072461A 2004-10-15 2007-05-14 Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme NO20072461L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61897504P 2004-10-15 2004-10-15
PCT/US2005/037215 WO2006044775A2 (en) 2004-10-15 2005-10-14 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
NO20072461L true NO20072461L (no) 2007-07-03

Family

ID=36203612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072461A NO20072461L (no) 2004-10-15 2007-05-14 Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme

Country Status (21)

Country Link
US (2) US7759376B2 (de)
EP (1) EP1805156B1 (de)
JP (1) JP2008516978A (de)
KR (1) KR20070063546A (de)
CN (1) CN101087769A (de)
AT (1) ATE492542T1 (de)
AU (1) AU2005295453A1 (de)
BR (1) BRPI0516483A (de)
CA (1) CA2583784A1 (de)
CR (1) CR9034A (de)
DE (1) DE602005025517D1 (de)
EA (1) EA200700851A1 (de)
EC (1) ECSP077397A (de)
ES (1) ES2357015T3 (de)
IL (1) IL182218A0 (de)
MA (1) MA28935B1 (de)
MX (1) MX2007004217A (de)
NO (1) NO20072461L (de)
TN (1) TNSN07111A1 (de)
WO (1) WO2006044775A2 (de)
ZA (1) ZA200703002B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
JP2009520786A (ja) 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
EP2402317B1 (de) 2006-03-31 2013-07-03 Novartis AG DGAT Inhibitor
NZ572586A (en) 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
KR20090010092A (ko) 2006-05-30 2009-01-28 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP5662803B2 (ja) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０
LT2303270T (lt) 2008-05-05 2017-09-11 Sanofi Acilamino-pakeistieji sulieti ciklopentankarboksirūgšties dariniai ir jų panaudojimas kaip vaistų
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
US20100168079A1 (en) * 2008-12-23 2010-07-01 Daniela Angst Biaryl Benzylamine Derivatives
EP2389366A1 (de) * 2009-01-23 2011-11-30 Msd K.K. Benzodiazepin-2-on-derivate
EP2805951B1 (de) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
AR079022A1 (es) * 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
NZ599855A (en) 2009-11-05 2014-06-27 Piramal Entpr Ltd Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity
MX341841B (es) 2009-12-16 2016-09-05 Pola Chem Ind Inc Agente de prevencion o mejoramiento para la pigmentacion.
US9061012B2 (en) 2010-03-30 2015-06-23 Novartis Ag Uses of DGAT1 inhibitors
KR101392334B1 (ko) 2011-05-03 2014-05-12 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2892896B1 (de) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
EP2892897A1 (de) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2015295376C1 (en) * 2014-08-01 2020-07-16 Bayer Pharma Aktiengesellschaft Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
CN105646510A (zh) * 2014-12-02 2016-06-08 重庆宁牧生态农业有限公司 一种用作抗肥胖剂的化合物
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
AU2020291464A1 (en) * 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) * 2020-10-19 2021-02-09 济南大学 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) * 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Also Published As

Publication number Publication date
JP2008516978A (ja) 2008-05-22
ZA200703002B (en) 2008-08-27
EP1805156A2 (de) 2007-07-11
WO2006044775A3 (en) 2006-06-15
MA28935B1 (fr) 2007-10-01
CN101087769A (zh) 2007-12-12
ECSP077397A (es) 2007-05-30
EP1805156A4 (de) 2009-06-10
IL182218A0 (en) 2007-09-20
EA200700851A1 (ru) 2007-12-28
BRPI0516483A (pt) 2008-09-02
TNSN07111A1 (en) 2008-06-02
MX2007004217A (es) 2007-06-11
ES2357015T3 (es) 2011-04-15
ATE492542T1 (de) 2011-01-15
EP1805156B1 (de) 2010-12-22
CA2583784A1 (en) 2006-04-27
DE602005025517D1 (de) 2011-02-03
KR20070063546A (ko) 2007-06-19
CR9034A (es) 2008-11-18
WO2006044775A2 (en) 2006-04-27
US7759376B2 (en) 2010-07-20
US20070265298A1 (en) 2007-11-15
AU2005295453A1 (en) 2006-04-27
US20110118302A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20091655L (no) Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer
EA200970946A1 (ru) Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201000098A1 (ru) Производные хиназолинамида
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
NO20073717L (no) Fenylmetanonderivater og deres anvendelse som glycin-transportor-1-inhibitorer
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application